MARK A MUNGER portrait
  • Professor, Pharmacotherapy
801-581-6165

Presentations

  • “Which Medications Can Be Stopped for Improvement and How?” . Invited Talk/Keynote, Presented, 09/2012.
  • “Estimating Clinical Pharmacy Work Load” . Invited Talk/Keynote, Presented, 04/2012.
  • “Heart Failure: Current Medical Therapy". Invited Talk/Keynote, Presented, 04/2012.
  • “Acute Decompensated Heart Failure Pharmacy Practice Workshop” . Invited Talk/Keynote, Presented, 04/2012.
  • “Double-Trouble: Co-Morbidities and Cases in Heart Failure—Drug Dosing” Presented to the 2011 Heart Failure Society of America 15th Annual Scientific Meeting, Boston, Massachusetts, September, 2011. Invited Talk/Keynote, Presented, 09/2011.
  • “Evaluation of Complementary and Alternative Medications in Cardiovascular Disease”. Presented to the 8th Annual Ponte Vedra Cardiovascular Symposium, Jacksonville, Florida, April, 2011. Invited Talk/Keynote, Presented, 04/2011.
  • “Burden of Atrial Fibrillation on HealthCare. On-Line Presentation through ScientiaCME. http://scientiacme.org/cmecoursecontent.php?ID=13&start=0&st=111. Other, Presented, 10/2010.
  • “How to Evaluate Supplements and Non-Cardiac Drug Interactions in Heart Failure Patients” Presented to the 2010 Heart Failure Society of American 14th Annual Scientific Meeting, San Diego, California, September, 2010. Presentation, Presented, 09/2010.
  • Hyponatremia. Presented to the Pharmacy Learning Network, Dallas, Texas, May, 2010; New York, NY, May, 2010; Washington D.C., September, 2010, and Philadelphia, PA., November, 2010. Presentation, Presented, 01/2010.

Languages

  • English, fluent.

Publications

  • Munger MA, Gordon E, Hartman J, Vincent K, Feehan M. Retail pharmacist satisfaction and stress study 2012. J Am Pharm Assoc 2013;53(3):30-44. Published, 05/01/2013.
  • Smock K, Schmidt R, Hadlock G, Stoddard G, Grainger DW, Munger MA. Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology 2013;Mar 22 [epub ahead of print]. Published, 03/22/2013.
  • Fihn SD, Gardin JM, Munger MA, et al. for the 2009 Guideline Committee for the Management of Patients with Stable Ischemic Heart Disease) A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2012;;(In Press). In press, 06/2012.
  • Munger MA Are All ARBs the Same? Pharm and Therapeutics 2011;3(1):22-31. Published, 01/2011.
  • Munger MA, Shane-McWhorter L, McAdam-Marx C. Prediabetes: Implications for Managed Care. Am J Pharmacy Benefits 2010;2(7):429-41. Published, 12/2010.
  • Munger MA. Polypharmacy and the management of hypertension in elderly patients with comorbid diabetes. Drugs and Aging 2010;Nov1:27(11):871-83. Published, 11/01/2010.
  • ACCP Publications Committee (Edward Bednarczyk, Michael Burton (Chair), Lisa Davis, George Davis, Mary Beth Elliott, Julie Maurey, Mark Munger (Vice-Chair), Terry Seaton, Daniel Touchette, and Jennifer Zimmer-Young) The Clinical Pharmacist as Principal Investigator: A Commentary from ACCP (2009) Pharmacother 2010;30(12)485e-89e. Published, 10/01/2010.
  • Lamb JG, Hathaway LB, Munger MA, Franklin MR. Nano-silver Particle Effects On Drug Metabolism. Drug Metabolism and Disposition. 2010:epub ahead of print September 22nd , 2010. Published, 09/22/2010.
  • Bakris GL, Sarafidis PA, Weir MR, DahlÅ‘f B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA: Accomplish Trial Investigators (Munger M). Renal outcomes with fixed-dose combination therapies in patients with hypertension at high-risk for cardiovascular events (ACCOMPLISH); A prespecified secondary analysis of a randomized clinical trial. Lancet 2010;375 (9721):1173-81. Published, 02/18/2010.
  • Duprez D, Munger M, Botha J, Charney AN. Aliskiren for Geriatric Lowering of Systolic Hypertension: Results of the AGELESS Trial. J Hum Hyper 2009;Dec 24:1-9 Epub ahead of print. Published, 12/01/2009.
  • Zebrack JA, Munger M, McGregor J, Stoddard GP, Gilbert EM. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure: A randomized dose ranging trial. Pharmacother 2009;29(8):883-90. Published, 08/01/2009.
  • Jackevicius C, Page R, Chow S, Dunn S, Lee C, Ng, T, Rodgers J, Verdany O, Wiggins B, Munger M. High-Impact Articles Related to the Management of Heart Failure: Update 2008 Pharmacother 2009;29(1):82-112. Published, 2009.
  • MacGregor JF, S Blake Wachter, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained benefits over 12 years of follow-up. Congestive Failure 2009;15(1):5-8. Published, 2009.
  • Van Tassell B, Radwanski P, Munger MA. Beta-blockers and phosphodiesterase inhibitors (PDEs) in chronic heart failure: Potential for combination therapy. Pharmacother 2008;28(12):1523-30. Published, 2008.
  • Van Tassell BW, Rondina M, Huggins F, Gilbert EM, Munger MA. Carvedilol increases blood pressure response to phenylephrine infusion in Class C heart failure subjects: Evidence of improved vascular α1-adrenoreceptor signal transduction. Am Heart J 2008;156(2):315-21. Published, 2008.
  • Jamerson K, Weber MA, Bakris GL, et al for the ACCOMPLISH Trial Investigators (Munger M). Benazapril plus amlodpine or hydrochorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28. Published, 2008.
  • Munger MA, Stoddard GP, Wenner AR, Bachman, J Jurige JH, Poe L, Baker D. Safety of e-medicine versus traditional medicine prescribing. Mayo Clinic Proceed 2008;83(8):890-6. Published, 2008.
  • Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK, for the MEDIC Study Group. Misoprostol Effects on Diclofenac-Induced Cardiorenal Changes. Pharmacother 2008;28(7):834-42. Published, 2008.